Work

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9514

Authors: Daniel Olson, Jason J. Luke, Sigrun Hallmeyer, Madhuri Bajaj, Timothy Carll, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Bruce Brockstein, Vernon K. Sondak, Zeynep Eroglu, Thomas Gajewski, Nikhil I. Khushalani

Institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, Oncology Specialists, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Chicago Medical Center, Endeavor Health, Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890199314

Cites:

Cited by: 20

Related to: 10